Department of Experimental Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Oncoimmunology. 2022 Apr 5;11(1):2060907. doi: 10.1080/2162402X.2022.2060907. eCollection 2022.
Myeloid-derived suppressor cells (MDSCs) are a population of immune suppressive cells that are involved in tumor-associated immunosuppression, and dominate tumor progression and metastasis. In this study, we report that the leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4, murine ortholog gp49B) orchestrates the polarization of MDSCs to exhibit pro-tumor phenotypes. We found that gp49B deficiency inhibited tumor metastases of cancer cells, and reduced tumor-infiltration of monocytic MDSCs (M-MDSCs) in tumor-bearing mice. Gp49B MDSCs inhibited pro-tumor immune responses, such as activation of Treg cells, promotion of cancer cell migration, and stimulation of tumor angiogenesis. Treatment of wild-type tumor-bearing mice with gp49B M-MDSCs reduced cancer metastasis. Furthermore, gp49B knockout affected plasma exosome composition in terms of increased miR-1 family microRNAs (miRNAs) expression, which correlates with the upregulation of gp49B MDSC-derived anti-tumor miRNAs. Collectively, our findings reveal that LILRB4/gp49B promotes MDSC-mediated tumor metastasis by regulating the M2-polarization of MDSCs and suppressing the secretion of miR-1 family miRNAs, which facilitate tumor migration and invasion. Abbreviations CTLA-4: cytotoxic T-lymphocyte-associated protein-4; FBS: fetal bovine serum; G-MDSCs: granulocytic-MDSCs; GP49B: glycoprotein 49B; HE: hematoxylin-eosin; ICI: immune checkpoint inhibitor; ITIM: immunoreceptor tyrosine-based inhibition motif; LILRB4: leukocyte immunoglobulin-like receptor B4; M-CSF: macrophage colony stimulating factor; MDSC: myeloid-derived suppressor cell; M-MDSC: monocytic MDSC; MMP-9: metallopeptidase-9; mAb: monoclonal antibody; PBS: phosphate-buffered saline; PCR: polymerase chain reaction; PD-1: programmed death-1; PD-L1: programmed death ligand-1; PMN-MDSC: polymorphonuclear-MDSC; qRT-PCR: quantitative reverse transcription PCR; TAM: tumor associated macrophage; TME: tumor microenvironment; TMM: trimmed mean of M value; VEGFA: vascular endothelial growth factor A.
髓系来源的抑制性细胞 (MDSCs) 是一种免疫抑制细胞,参与肿瘤相关的免疫抑制,并且主导肿瘤的进展和转移。在这项研究中,我们报告白细胞免疫球蛋白样受体亚家族 B 成员 4 (LILRB4,鼠同源物 gp49B) 协调 MDSC 的极化以表现出促肿瘤表型。我们发现 gp49B 缺陷抑制了癌细胞的转移,并减少了荷瘤小鼠中单核细胞 MDSC (M-MDSC) 的肿瘤浸润。gp49B MDSC 抑制了促肿瘤免疫反应,例如 Treg 细胞的激活、促进癌细胞迁移和刺激肿瘤血管生成。用 gp49B M-MDSC 治疗野生型荷瘤小鼠可降低癌症转移。此外,gp49B 敲除影响了血浆外泌体组成,表现为 miR-1 家族 microRNAs (miRNAs) 表达增加,这与 gp49B MDSC 衍生的抗肿瘤 miRNAs 的上调相关。总之,我们的研究结果表明,LILRB4/gp49B 通过调节 MDSC 的 M2 极化和抑制 miR-1 家族 miRNAs 的分泌来促进 MDSC 介导的肿瘤转移,从而促进肿瘤迁移和侵袭。缩写词 CTLA-4:细胞毒性 T 淋巴细胞相关蛋白-4;FBS:胎牛血清;G-MDSCs:粒细胞-MDSC;GP49B:糖蛋白 49B;HE:苏木精-伊红;ICI:免疫检查点抑制剂;ITIM:免疫受体酪氨酸抑制基序;LILRB4:白细胞免疫球蛋白样受体 B4;M-CSF:巨噬细胞集落刺激因子;MDSC:髓系来源的抑制性细胞;M-MDSC:单核细胞 MDSC;MMP-9:金属蛋白酶-9;mAb:单克隆抗体;PBS:磷酸盐缓冲盐水;PCR:聚合酶链反应;PD-1:程序性死亡-1;PD-L1:程序性死亡配体-1;PMN-MDSC:多形核-MDSC;qRT-PCR:定量逆转录 PCR;TAM:肿瘤相关巨噬细胞;TME:肿瘤微环境;TMM:M 值修剪均值;VEGFA:血管内皮生长因子 A。